Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease

Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease

<i>Background and Objectives</i>: The subcutaneous (SC) formulation of vedolizumab has proven to be effective for the maintenance of remission after intravenous induction. Little is known about the efficacy of switching from intravenous maintenance treatment to SC. We aimed to assess the...

Full description

Bibliographic Details
Main Authors: Špela Pintar, Jurij Hanžel, David Drobne, Matic Koželj, Tina Kurent, Nataša Smrekar, Gregor Novak
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Medicina
Subjects:
inflammatory bowel disease
Crohn’s disease
ulcerative colitis
vedolizumab
subcutaneous formulation
Online Access:https://www.mdpi.com/1648-9144/60/2/296

Similar Items

Similar Items